David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 20 years of covering Asia Pacific equities, the past 16 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Hard catalysts (M&As, spin-offs, demergers) & discount arbitrage (holdco, share-class)

Event-Driven

Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sihuan-pharmaceutical-hldgs" target="_blank" data-smartkarma-citation="entities:33:1" rel="noopener"><strong>Sihuan Pharmaceutical (460 HK)</strong></a> has shot down rumours that it is under negotiation with potential investors in respect of privatisation.</li>
<li>Reportedly SOE China Resources is in talks with Sihuan Pharma's chairman in a deal valuing the company at US$3bn or a 114% premium to the current price. </li>
<li>The logic of a privatisation makes sense. I would not be so quick to dismiss the denial. Plus Sihuan Pharma is very cash-rich.</li>
</ul>

Sihuan Pharmaceutical Hldgs

Sihuan Pharma (460 HK) Denies China Resources Approach